Cours suspendu

Communiqués Poseida Therapeutics, Inc.

Actions

PSTX

US73730P1084

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/01/2025			Varia. 5j.	Varia. 1 janv.
9,500 ^USD	-0,63%		-.--%	-

08/01/25	L'indice du marché suisse poursuit sa progression ; Partners Group gagne du terrain	MT
08/01/25	L'acquisition de Poseida Therapeutics est sur le point d'être finalisée, selon Roche	MT

Communiqués

28/11/24	POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX	BU
27/11/24	Poseida Therapeutics, Inc. Announces Agreement to be acquired by Roche Holdings, Inc.	AQ
26/11/24	Poseida Therapeutics : Announces Agreement to be Acquired by Roche Holdings, Inc Form 8 K	PU
14/11/24	Poseida Therapeutics : Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline Form 8 K	PU
14/11/24	Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline	PR
11/11/24	Poseida Therapeutics to Present at Two Upcoming Investor Conferences	PR
07/11/24	Poseida Therapeutics : Provides Updates and Financial Results for the Third Quarter of 2024 Form 8 K	PU
25/10/24	Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema	AQ
17/10/24	Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche	PR
04/10/24	Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024	AQ
27/09/24	Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients	PR
16/09/24	Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma	PR
05/09/24	Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting	PR
04/09/24	Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma	PR
29/08/24	Poseida Therapeutics to Present at Upcoming Investor Conferences	PR
06/08/24	Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024	AQ
01/07/24	Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum	PR
03/06/24	Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders	PR
10/05/24	Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting	AQ
02/05/24	Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	PR
01/05/24	Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	PR
19/04/24	Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting	AQ
17/04/24	Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus	PR
01/04/24	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PR
19/03/24	Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	PR